Dr. Natalie Sinclair
Hematology & Oncology (Hematology & Oncology Physician)
20 Prospect St
Milford, MA 01757
Who else practices at this address →
Worcester County includes primary care (3% of residents) and mental health (11% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Vermont College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 418
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Vermont College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 254223 -
Internal Medicine Physician
VT license 060-000-3432
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
- Milford Regional Medical Center Milford, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 418
- Services billed
- 770
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 613 | 319 |
| New patient office or other outpatient visit, 60-74 minutes | 55 | 55 |
| Telephone medical discussion with physician, 11-20 minutes | 45 | 37 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 30 |
| Established patient office or other outpatient visit, 40-54 minutes | 16 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 16 | 11 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Milford, MA | 268 |
| Anastrozole Other prescribers in Milford, MA | 95 |
| Duloxetine Hcl Other prescribers in Milford, MA | 34 |
| Tamoxifen Citrate Other prescribers in Milford, MA | 33 |
| Exemestane | 32 |
| Ondansetron Odt (ondansetron) Other prescribers in Milford, MA | 25 |
| Verzenio (abemaciclib) | 22 |
| Hydroxyurea Other prescribers in Milford, MA | 22 |
| Lenalidomide | 21 |
| Dexamethasone Other prescribers in Milford, MA | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $5,621 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.